$101.92
Benzinga
Benzinga
Benzinga
화요일, 9월 15
Abbott Laboratories
ABTNYSE
Abbott Laboratories Earnings & Forecasts
Abbott Laboratories (ABT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Abbott Laboratories Guidance
Abbott Laboratories (ABT)은 지난 7월 16, 2026에 Q3 2026의 실적 전망을 발표했습니다. 회사는 주당순이익을 $1.38 - $1.46 범위로 전망했으며, 이는 시장 컨센서스 EPS 추정치인 $1.42보다 높은 수치입니다.
이전 가이던스와 비교하여 Abbott Laboratories는 주당순이익(EPS) 전망치를 이전 범위인 하향 조정됨에서 $5.45 - $5.6로 상향 조정했습니다.
Abbott Laboratories은 27과 10월 19, 2022 사이에 7월 16, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 6 times and lowered it 10 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.28 | $1.14 | $1.50 | $1.30 |
| Actual | $1.31 | $1.15 | $1.50 | $1.30 |
| Surprise | +2.34% | +0.88% | 0.00% | 0.00% |
| Revenue | ||||
| Estimate | $12.51B | $11.01B | $11.80B | $11.40B |
| Actual | $12.59B | $11.16B | $11.46B | $11.37B |
| Surprise | +0.66% | +1.43% | -2.87% | -0.30% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.42 | $1.64 | $1.30 | $1.49 |
| Revenue | ||||
| Consensus | $12.98B | $13.52B | — | — |
Earnings & Guidance News
Benzinga
© 2026 Benzinga | All Rights Reserved